Myriad Genetics, Inc. (MYGN) Partners With PharmaMar S.A. for New HRD Test
3/29/2013 8:23:55 AM
More...
|
Spanish Biotech PharmaMar S.A. Selects Medidata Solutions, Inc. Clinical Cloud to Accelerate Trials for Marine-Based Oncology Drugs
3/18/2013 10:07:36 AM
More...
|
PharmaMar S.A. Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
2/8/2011 8:14:33 AM
More...
|
PharmaMar S.A. Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients
6/9/2010 10:06:36 AM
More...
|
PharmaMar S.A. Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
4/22/2010 10:58:40 AM
More...
|
Zeltia Group (18494051.MA)'s PharmaMar S.A. in Deal With US Medimetriks Pharmaceuticals, Inc.
6/10/2009 7:20:23 AM
More...
|
Innovex (INVX) to Promote PharmaMar S.A.'s Yondelis(R) Cancer Treatment
12/3/2007 9:17:09 AM
More...
|
Dr. Enrique Sendagorta Appointed Managing Director Of PharmaMar S.A.
1/22/2007 10:58:27 AM
More...
|
PharmaMar S.A. Release: Successful Planned Independent Analysis Of Pivotal Phase III Trial Of YONDELIS® In Ovarian Cancer
10/6/2006 11:52:18 AM
More...
|
PharmaMar S.A. Reports New Data On Kahalalide-F And Aplidin(R) At ESMO Congress
9/29/2006 4:12:55 PM
More...
|
|